

AD _____

Award Number: W81XWH-15-1-0120

TITLE:

Identification of Androgen Receptor-Specific Enhancer RNAs

PRINCIPAL INVESTIGATOR:

Yin-Yuan Mo

CONTRACTING ORGANIZATION:

University of Mississippi Medical Center
Jackson, MS 39216

REPORT DATE:

June 2016

TYPE OF REPORT:

Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE				Form Approved OMB No. 0704-0188	
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.					
1. REPORT DATE June 2016		2. REPORT TYPE Annual		3. DATES COVERED 15 May 2015 - 14 May 2016	
4. TITLE AND SUBTITLE Identification of Androgen Receptor-Specific Enhancer RNAs				5a. CONTRACT NUMBER	
				5b. GRANT NUMBER W81XWH-15-1-0120	
				5c. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S) Yin-Yuan Mo E-Mail: ymo@umc.edu				5d. PROJECT NUMBER	
				5e. TASK NUMBER	
				5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) University of Mississippi Medical Center 2500 State Street, G652 Jackson, MS 39216				8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012				10. SPONSOR/MONITOR'S ACRONYM(S)	
				11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited					
13. SUPPLEMENTARY NOTES					
14. ABSTRACT The major goal of this application is to determine whether prostate cancer cells express enhancer RNAs in response to androgen treatment such that these enhancer RNAs may serve as novel biomarkers for prostate cancer diagnosis and prognosis. There are two Tasks in this application. First, we will perform global run-on assay and deep sequencing to identify AR-specific enhancer RNAs. Second, we will validate them and then determine their functional significance. The success of this study may lead to novel clinical applications such as identification of biomarkers or therapeutic targets for prostate cancer, especially for castration resistant prostate cancer.					
15. SUBJECT TERMS lncRNA, eRNA, biomarker					
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT	18. NUMBER OF PAGES	19a. NAME OF RESPONSIBLE PERSON
a. REPORT	b. ABSTRACT	c. THIS PAGE			USAMRMC
U	U	U	UU		19b. TELEPHONE NUMBER (include area code)

Table of Contents

	<u>Page</u>
Introduction.....	1
Body.....	1
Key Research Accomplishments.....	N/a
Reportable Outcomes.....	N/a
Conclusion.....	N/a
References.....	N/a
Appendices.....	N/a

Introduction

The androgen receptor (AR) is a nuclear receptor transcription factor required for normal prostate development and prostate cancer pathogenesis. AR is a very important druggable target. For instance, androgen deprivation therapy (ADT) is a frontline treatment for advanced prostate cancer. However, despite initial response, patients become resistant to ADT due to castration resistance. Extensive studies have suggested that multiple factors contribute to castration resistance. We hypothesize that long non-coding RNAs (lncRNAs) is one of the important factors, especially those AR specific enhancer RNAs (eRNAs), contributing to castration resistance. In this application, we proposed to determine whether we can identify such AR specific eRNAs.

There are two major tasks for this project:

Task 1. Perform global run-on assay and deep sequencing to identify AR-specific enhancer RNAs

Task 2. Validation and functional significance of AR specific eRNAs

We have finished Task 1 so far. Major findings are reported below

Body

Profiling identified several potential eRNAs that are induced by androgen.

As newly discovered molecules, eRNAs are poorly characterized. Little is known whether they are dysregulated in prostate cancer. Thus, our first step was to characterize these new molecules by profiling. Results indicate that a number of eRNAs are upregulated in response to androgen treatment. Bioinformatics analysis further narrows down three interesting eRNAs and their sequences are shown below.

AR-eRNA-#1 (117 bp)

```
caccattacacaggactgcctttcaggaagggttctctgccactggaaaagggtacagcttttctagagggcaatagg  
tgatttctattaaaatatcaaagacacactccttgccctt
```

This eRNA is localized to chr14:24408289-24408405. Literature search indicates that it is homologous to AS1eRNA that may enhance another lncRNA called *DHRS4-AS1*

AR-eRNA-#2 (504 bp)

```
>hg19_dna range=chr18:54746000-54746503
tgggaaaaagacctgcagacggcctgccaggggcccccggtctgtgtg
cccaggtgaggccttaggaggaggcagcagtggtgtcgaggaggaggatt
caggcctcctgggctgtccagggttttagccaaccatcaatgggcgaaac
agagccgctatcctgacttccacatacaagcattagaaatctcctcttgt
acaaaggaagaccatatcccaaccatacatgtgcacttgactcaatggct
gtgctatcaagtgggaggggacatccagccctgggtcccccggtcctagc
catctgtatgtactaaggacactgtctctcagagcctgcaaactgcat
cctgcaatacccatgagtcactcaccttctcagaggagccttttctggc
aattctgttgaatgttgccccaaccctgtattccctacacactgcctgct
ttattttctctatagctgtgggtcacaattggacggactgtatattttact
tatt
```

Bioinformatics analysis mapped this sequence at the upstream of the potential promoter of Linc-RoR.

Linc-RoR is known for its role in stem cell maintenance. Our lab has also demonstrated that Linc-RoR is a repressor for p53 in response to DNA damage. Furthermore, Linc-RoR increases Myc mRNA stability through interaction with hnRNP I and AUF1. Thus, identification of this potential eRNA that may regulate Linc-RoR will provide new insight into lncRNA regulation in prostate cancer, further implying that Linc-RoR might be also controlled by androgen.

AR-eRNA-#3 (468 bp)

```
>hg19_dna range=chr19:51354315-51354782
tgcctcccaacactgttcagccagagccttccacccttgtctgcaggaca
gtctcaacgttccaccattaaatacttcttctgtcacatcctgcttattt
atgcctaaccaaggttctaggtcccgatcgactgtgtctggcagcactcc
actgccaaccagaataaggcagcgctcaggatcccgaaggggcatggc
tggggatcagaacttctgggtttgagtgaggagtgggtccaccctcttga
atltcaaaggaggaagaggctggatgtgaaggaactgggggagggaaagt
gtcagttccgaactcttaggtcaatgaggaggagactggtaagggtccca
gctcccaggtactgatgtgggaatggcctaagaatctcatatcctcagg
aagaaggtgctggaatcctgaggggtagagttctgggtatattttgtggct
taaggctcttttgccct
```

Bioinformatics analysis indicated that this sequence is homologous to KLK3e which is a known androgen inducible eRNA. Of interest, KLK3e has been shown to positively regulate Kallikrein-related peptidase 3 (KLK3), which codes for prostate-specific antigen (PSA); PSA is a well-known AR-regulated gene.

Together, these results suggest that there exist a group of AR-regulated eRNAs which may impact prostate tumorigenesis. Thus, further characterization of these eRNAs will provide a better understanding of AR-mediated gene regulation and castration resistance, and thus it will help design a better strategy for prostate cancer therapy.

Future work

We will focus on these three candidate eRNAs to perform experiments as stated in Task 2 of SOW. In brief, we will first verify their expression by qRT-PCR. Based on their expression in response to androgen, we will determine whether they are differentially expressed in androgen sensitive and androgen insensitive (i.e., castration resistant) cell lines such as LNCaP and 22Rv1 cells. Finally, we will then determine whether they play a role in castration resistance.